Does MEDVi QUAD Still Have Apomorphine? What Changed, and What Nobody Has Explained

Short answer: no, it doesn't. Apomorphine came out of QUAD on July 16, 2026. The longer and more useful answer is what apomorphine actually does, the single reason MEDVi gave for the change, the parts of the story that remain unexplained, and which competing products still contain it.

What Changed and When

On July 16, 2026, MEDVi reformulated QUAD. The blend went from sildenafil, tadalafil, vardenafil, and apomorphine to sildenafil, tadalafil, L-citrulline, and PT-141 (bremelanotide). Two ingredients out, two in. MEDVi announced it in a press release on July 18, 2026, and the company's live product page now lists PT-141 and L-citrulline.

That is the entire verified factual record of the change. If you land on a page that still describes apomorphine as one of QUAD's four active ingredients, that page has not been updated since mid-July. We've also seen the opposite error — pages that correctly caught the swap but then attached apomorphine's history to PT-141, which is a different drug in a different class entirely.

The question this page exists to answer is the one that follows naturally and that almost nobody has attempted: why. We'll be straight with you up front — MEDVi has not answered it, and we are not going to invent an answer. What we can do is lay out what apomorphine is, what the company did say, what the change means mechanically, and what it means for you depending on how the old formula treated you.

What Apomorphine Actually Is

Despite the name, apomorphine is not an opioid and it isn't a form of morphine. It's a dopamine agonist — a compound that stimulates dopamine receptors. It's used in Parkinson's disease, where the underlying problem is a dopamine deficit, and that's the context most physicians know it from.

For erectile function, the logic is that arousal signalling runs partly through dopamine pathways in the brain. Apomorphine engages that system rather than the vascular one. It doesn't dilate blood vessels the way sildenafil and tadalafil do; it works upstream of that, on the signal rather than the plumbing.

Two things need saying plainly, because a lot of coverage gets one or both of them wrong in opposite directions.

Apomorphine has genuine clinical evidence for erectile dysfunction. This is not a novelty ingredient or an untested additive. It has published human data behind its use in ED and a real history of being used for it. Anyone framing its removal from QUAD as the correction of some obvious error is overstating what happened.

Apomorphine is strongly associated with nausea. This is its best-documented drawback and the one men who've taken it tend to report first. Dopamine agonists act on the same receptor system involved in the vomiting reflex, which is why nausea follows the drug rather than being an odd coincidence.

The Only Reason MEDVi Gave

MEDVi's stated reason for the reformulation is that the new blend tastes better, which the company says improves approval rates. That's it. That's the public explanation.

For a sublingual liquid you hold under your tongue for a minute and a half, taste is not a trivial concern — a formula people won't take is a formula that doesn't work, and MEDVi is explicitly tying palatability to how many prescriptions get approved and filled. So the reason is coherent on its own terms.

But notice what it doesn't do. It's a statement about the formula as a whole, not about apomorphine specifically. MEDVi has not published apomorphine-specific reasoning. It has not said the ingredient was the taste problem, has not said anything about tolerability, and has not disclosed any safety finding. Vardenafil came out in the same change and got no individual explanation either.

So here is the part most sites skip: we don't know why apomorphine specifically was removed. Not "we suspect but can't confirm" — we genuinely do not know, and neither does anyone else writing about this. Reformulations happen for a long list of unglamorous reasons: sourcing, compounding pharmacy logistics, cost, stability in solution, tolerability feedback, palatability, or a straightforward bet that a different ingredient performs better. Any one of those is plausible. None is established.

We'd rather tell you we don't know than hand you a confident-sounding theory. If MEDVi publishes ingredient-level reasoning, we'll update this page.

What Replaced It, and Why It's a Different Mechanism

Apomorphine's role in the old QUAD was the desire ingredient — the one addressing arousal in the brain rather than blood flow. PT-141 (bremelanotide) now occupies that role, with L-citrulline added alongside it on the vascular side.

Both act centrally. That's where the similarity stops. They work through entirely different receptor systems:

The practical consequence: this is a substitution, not an upgrade path. If dopaminergic stimulation was what worked for you, a melanocortin agonist is not the same thing delivered a different way. It's a different lever.

PT-141's own status deserves stating precisely, since it's routinely mangled elsewhere. It's FDA-approved as Vyleesi, at 1.75 mg by subcutaneous injection, for hypoactive sexual desire disorder in premenopausal women. It is not approved for ED and not approved in men. In men, early-phase trials of intranasal bremelanotide showed erectogenic effects, including in some sildenafil non-responders, but ED development was halted, partly over blood-pressure concerns. In QUAD its use is compounded, off-label, and prescriber-supervised. It also produces a transient rise in blood pressure and is contraindicated in uncontrolled hypertension and known cardiovascular disease — which cuts against the PDE5 inhibitors in the same dose, since those lower blood pressure.

Who Still Has Apomorphine

QUAD's reformulation did not start a trend. The two closest competing sublingual products kept their formulas exactly as they were, which means apomorphine is still readily available — just not from MEDVi.

To be explicit, because this is where a lot of comparison content quietly editorializes: BlueChew and Rugiet are not doing anything wrong by continuing to include apomorphine. One company changing its formula is not a verdict on the ingredient, and no regulator has told anyone to stop using it. They made a different formulation choice, which they are entitled to make.

One caveat if you're weighing BlueChew Gold on the strength of its second desire ingredient: sublingual oxytocin has roughly 4.5% bioavailability with about tenfold variation between individuals, and the researchers who measured it concluded the sublingual route "would not seem a reliable route." There are no published RCTs for oxytocin in ED. That's a comment on oxytocin, not on apomorphine — Gold's apomorphine content is the same as Rugiet's. Our QUAD vs BlueChew Gold comparison goes through that in more depth, and the Rugiet Ready review covers the simpler three-ingredient option.

What This Means for You

Strip away the pharmacology and there are only two situations that actually matter, and which one you're in depends entirely on how apomorphine treated you.

If apomorphine's nausea was a problem for you

Then QUAD is now the option in this category that doesn't contain it. If you tried a sublingual blend previously and the nausea was bad enough that you stopped, or you dreaded taking it, the current QUAD formula removes that specific variable. That is a real, concrete reason to look at it again — with the significant caveat in the next section, which we'd ask you to read before deciding.

If apomorphine worked well for you

Then be aware that QUAD no longer offers it, and switching to QUAD means losing it. PT-141 is not apomorphine in a new wrapper; it's a different receptor system. If the old QUAD suited you and you're happy on it, the products that still contain apomorphine are BlueChew Gold and Rugiet Ready. That's not us steering you away from QUAD — it's the accurate answer to "where do I get the thing that was working?"

And if you've never taken either ingredient, you're choosing between two central-acting compounds with no head-to-head trial between them. Nobody has published one. In that situation the deciding factors are usually practical rather than pharmacological: what your prescribing clinician thinks given your history, especially your cardiovascular history, since PT-141 carries blood-pressure contraindications apomorphine doesn't share.

The Nausea Trade-Off Nobody Wants to Mention

Here's the part that gets left out of nearly every write-up of the reformulation, and it's the single most useful thing on this page.

Apomorphine is strongly associated with nausea. So is PT-141. Removing one and adding the other relocated the problem — it did not eliminate it.

In the pooled phase 3 trials for Vyleesi, PT-141's FDA-approved injectable form, nausea was reported by 40% of patients versus 1% on placebo. It's strongly front-loaded: 21% after the first dose, dropping to roughly 3% on subsequent doses. Median onset is within an hour and it lasts about two hours. In those trials 13% of patients used an anti-emetic and 8% discontinued over it. Flushing was reported at 20%, injection-site reactions at 13%, and headache at 11%.

What we can't tell you is the honest bottom line here: nobody has published data comparing nausea rates between old-formula QUAD and new-formula QUAD. No trial, no post-marketing dataset, nothing. It is entirely possible the new formula is easier on the stomach. It's also possible it isn't. If someone tells you confidently which way it goes, ask them for the citation.

The practical advice is unchanged regardless: take your first dose on an evening with no obligations, and tell your prescriber if it doesn't settle after the first few uses. Our full QUAD review covers the rest of the current formula in detail.

Frequently Asked Questions

Related